Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Auceliciclib dose-escalation and temozolomide combination study in advanced solid tumors and recurrent high-grade glioma
ACTRN12621000479808Phase 2Completed
- Sponsor
- Aucentra Therapeutics
- Start
- Jun 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of auceliciclib and temozolomide in Nonhematologic neoplasms, glioblastoma (GBM), glioma and 1 more (2 arms), sponsored by Aucentra Therapeutics. Primary endpoints: Safety and tolerability of auceliciclib monotherapy and Safety and tolerability of auceliciclib plus temozolomide. Started Jun 2021; status: completed.
02
Drugs
auceliciclibtemozolomide
03
Conditions
Nonhematologic neoplasmsglioblastoma (GBM)gliomacancer
Beyond the preview
Go deeper on ACTRN12621000479808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000479808.